Persistence of anti-SARS-CoV2 antibodies in infants born during 2021-2023 to the mothers who had received COVID-19 vaccination during pregnancy

ational Vaccine Institute0 个研究点目标入组 250 人开始时间: 2023年3月24日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Healthy neonates or infants, aged 0 days to 4 months old, (gestational age more than 32 weeks at birth) born to mothers aged 18 to 45 years old who received at least 1 dose of any COVID-19 vaccine types (mRNA, viral-vector or inactivated vaccine) in any of the following period:
•- at least 1 dose or recent booster dose within 3 months before pregnancy
•- during pregnancy but not exceed 2 weeks before delivery

•Neonates or infants who had any medical-related problems for example preterm (GA < 32 weeks at birth), congenital anomalies, severe birth infection or complications, immune deficiency and receiving any blood components products or immunomodulators as well as pregnant women with severe medical illnesses (e.g., exposure to immunosuppressive drugs, HIV infection, severe sepsis) that might affect antibody responses must be excluded from this study.

发起方

ational Vaccine Institute